Skip to content

Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate

Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00472563
Acronym
PROMEC
Enrollment
212
Registered
2007-05-11
Start date
2007-05-31
Completion date
2008-02-29
Last updated
2008-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Failure

Keywords

bicarbonate, nephropathy, contrast

Brief summary

Deterioration of kidney renal function occurs in a minority of people due to contrast-required procedures. The purpose of this study is to compare two different interventions to reduce the risk of kidney injury after contrast medium exposition. We will perform a randomized clinical trial following a modification of a previously published protocol (Merten et al.JAMA 2004;291(19):2328-34). Patients will be randomly assigned to one of two groups of treatment. Group A will receive 1 cc/kg/hour of 0.9% saline infusion starting 12 hours before and continuing 12 hours after the procedure. Group B will receive 3 cc/kg of sodium bicarbonate solution for one hour prior to procedure, then drip rate will be decreased to 1 cc/kg/hour until 6 hours post procedure.

Detailed description

We will perform a randomized clinical trial following a modification of a previously published protocol (Merten et al.JAMA 2004;291(19):2328-34). Patients will be randomly assigned to one of two groups of treatment. Group A will receive 1 cc/kg/hour of 0.9% saline infusion starting 12 hours before and continuing 12 hours after the procedure. Group B will receive 3 cc/kg of sodium bicarbonate solution for one hour prior to procedure, then drip rate will be decreased to 1 cc/kg/hour until 6 hours post procedure. Phase 2/3 study Study Type: Interventional Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study. Subjects: Consecutive samples of all inpatients who meet the inclusion criteria Primary outcomes: Development of contrast induced nephropathy, defined as an increase in serum creatinine of 25% or more within 48 h after administration of contrast. Secondary outcomes: change in serum bicarbonate; change in serum potassium; change in serum creatinine. Expected total enrollment: 212 Allocation Assignment: Patients who meet inclusion criteria and agree to participate in the study will be assigned by a random number table to saline or bicarbonate, using closed envelopes and stratifying according to history of diabetes and type of procedure (cardiac catheterism or others). Condition: Contrast Induced Nephropathy Intervention: 75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W Gender: both Age: 18+ years of age Recruitment Status: participants are currently being recruited Facility location: Universidad de Antioquia, Internal Medicine Department; Hospital Universitario San Vicente de Paul. Medellin, Colombia.

Interventions

DRUGBicarbinate 150 mEq/L

75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W

Sponsors

Universidad de Antioquia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* 18+ years of age * Inpatient at Hospital Universitario San Vicente de Paúl scheduled to undergo diagnostic CT scan using contrast or angiography and either * Serum creatinine 1.2 mg/dl or more, or * Type 2 Diabetes Mellitus

Exclusion criteria

* Current clinical diagnosis of exacerbated congestive heart failure * Exposure to contrast 30 days prior to study * Allergy to contrast dye * Chronic renal disease with dialysis therapy * Acute renal failure with dialytic urgency * Urgency procedure needed * Systolic blood pressure \< 90 or vasopressor support * No authorization by patient or physician in charge * Serum potassium \< 3 mEq/L * Ejection fraction \< 35% by previous echocardiography * Acute pulmonary edema in previous 48 hours

Design outcomes

Primary

MeasureTime frame
development of contrast induced nephropathy, defined as an increase in serum creatinine of 25% or more within 48 h after administration of contrast48 h

Secondary

MeasureTime frame
change in serum bicarbonate; change in serum potassium; change in serum creatinine48 h

Countries

Colombia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026